scholarly journals A Study of Dyslipidemia in Patients of Chronic Kidney Disease of Rural Population of Eastern Bihar- A Cross Sectional Observational Study Based on a Tertiary Care Hospital Set-Up

2021 ◽  
Vol 09 (11) ◽  
Author(s):  
Dr Suman Kumar Singh ◽  
Author(s):  
Hamad Jeelani ◽  
Manzoor A. Parry ◽  
Shruti Dange

Background: Chronic kidney disease (CKD) patients are at high risk of depressive disorders because of considerable psychological stress due to physical and social changes brought on by disease. The aim of this study is to assess the prevalence of depression in patients with CKD and the factors affecting it at a public tertiary care hospital. Methods: This cross-sectional study was carried out at the renal clinic of a tertiary care hospital. Data on 629 patients diagnosed with CKD from September 2014 to April 2016 was obtained. Nine-item Patient Health Questionnaire from PRIME-MD was used to assess the depression. Results: Of all the patients, 44.7% had depression. Mild depression was found to affect 28.9% of the patients followed by moderate depression and severe depression (15.4% and 0.4%, respectively). According to multiple logistic regression, the occurrence of depression was significantly higher with age below 60 years [odds ratio (OR) 1.5, 0.9–2.7; P<0.05], male gender (OR 1.4, 1.0–3.1; P<0.05), no treatment funding (OR 2.7, 1.3–4.6; P<0.05), education less than grade 12 (OR 1.3, 1.3–3.2; P<0.05), monthly income ≤INR 20,000 (OR 1.6, 1.1–3.6; P<0.05), CKD stage V (OR 1.4 1.0– 2.9; P <0.05), Patients on hemodialysis (HD) (OR 2.5, 1.2–4.5; P<0.05), comorbidities ≥3 (OR 1.6, 1.3–3.0; P<0.05), overweight (OR 2.4, 1.3–2.9; P<0.05), and duration of CKD >2 (OR 2.4, 1.4–4.4; P<0.05). Conclusion: About 44.7% of the patients were found to have depression. Patients’ age, gender, body mass index, treatment funding, education status, income, CKD duration and stage, HD status, and comorbidities were found to be significant factors affecting depression.


2020 ◽  
pp. 1-3
Author(s):  
Sujana C N ◽  
Niranjan M R ◽  
Parashivamurthy B M

Background: Poly-pharmacy being most common in chronic kidney disease patients (CKD). The present study was carried out to analyse current prescribing trends in the management of CKD patients and to compare it with WHO Core Indicators. Methods: A prospective observational study was carried out for three months (15th July 2019 – 15th October 2019) after Institutional Ethics Committee approval at a tertiary care hospital. Patients diagnosed with CKD by treating Nephrologist were included and their prescriptions (OPD card) were analysed to study the prescribing patterns. Results: A total of 60 cases were analysed during the study, of which 73.3% were males and 26.7% were females. The common comorbidities were hypertension (36.6%), diabetes (36.6%), other cardiovascular diseases (26.6%), anaemia (3.33%), Ca Cervix (1.67%), osteoarthritis (6.67%). Among drugs Antihypertensive drugs (40.9%) were the most commonly used drugs, followed by, Anti-diabetic drugs, calcium salts and multi-vitamins (19.7%), oral iron supplements and erythropoietin (13.4%) and ulcer protective (6.1%). Conclusions: Polypharmacy being followed in these CKD patients were necessary for multiple conditions of patient, supplemental drugs decreased adverse effects on initial drug and they yielded synergistic effects. Maximum numbers of drugs were prescribed from anti-diabetic, antihypertensive, supplemental drugs and other cardiovascular class of drugs. The principle of rational prescribing was followed. The right choice of drugs and in appropriate doses will reduce the incidence of nephrotoxicity and ultimately result better clinical outcomes.


Author(s):  
Nandini Chatterjee ◽  
Supratick Chakraborty ◽  
Mainak Mukhopadhyay ◽  
Sinjon Ghosh ◽  
Bikramjit Barkandaj ◽  
...  

2019 ◽  
Vol 6 (2) ◽  
pp. 271
Author(s):  
Vishnu Shankar H. ◽  
Mahendra Kumar K. ◽  
Jagadeesan M. ◽  
Kannan R. ◽  
Chitrambalam P. ◽  
...  

Background: Secondary hyperparathyroidism (SHPT) is one of the less recognized complications in patients with chronic kidney disease (CKD). The prevalence of SHPT in various stages of CKD was evaluated by measuring the levels of intact parathyroid hormone (iPTH).Methods: This cross-sectional study was carried out in 100 CKD patients. Serum creatinine, calcium, phosphorous and iPTH levels were measured and statistical analysis was carried out using the SPSS software (IBM, NY, USA).Results: Among the 100 participants, the mean age (SD) was 59.3 (7.8) years. In our study population, 52% were men and the rest were females. Hypertension (75%) was the most common chronic morbidity. Prevalence of hyperparathyroidism among chronic kidney disease patients was 22% (95% CI: 14.7-30.9%). The prevalence of secondary hyperparathyroidism among dialysis and non-dialysis patients were 30% and 14% respectively which was statistically significant.Conclusions: SHPT is an important complication which is often underdiagnosed. Secondary hyperparathyroidism starts to develop when eGFR falls below 60ml/min. PTH levels starts to rise as the disease progress. Hence it is important for the treating physicians to monitor the PTH levels early in the course of CKD to prevent and treat bone mineral disease.


Sign in / Sign up

Export Citation Format

Share Document